Drug maker Lupin on Thursday reported a consolidated net loss of Rs 89 crore for the first quarter ended June 30 due to lower sales in the US market.
The Mumbai-based drug maker had posted a net profit of Rs 542 crore in the April-June quarter of the last fiscal.
Its total revenue from operations stood at Rs 3,744 crore in the June quarter compared to Rs 4,270 crore in the year-ago period, Lupin said in a statement.
"Our numbers are muted this quarter, but we expect a strong bounce back from Q2 onwards. Our US sales took a significant dip as we took several strategic decisions to pave the way for building a sustainable and profitable business," Lupin Managing Director Nilesh Gupta said.
During the quarter, the company pared down inventories and took shelf stock adjustments on select products, he added.
"We have now implemented several optimisation measures, including addressing our workforce in operations and supporting functions to improve our cost position and ensure competitiveness.
"While the benefits of this optimisation will start accruing Q2 onwards, we are now focused on getting back on the growth path driven by growth in key markets like India and multiple important complex generic launches in the US and other developed markets," Gupta said.
On the compliance front, the company has now satisfactorily addressed issues at both Goa and Somerset plants, he added.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve hit your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Quarterly Starter
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories Online
Over 30 behind the paywall stories daily, handpicked by our editors for subscribers


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app